CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...
Saved in:
Main Authors: | Amrallah A. Mohammed (Author), Hanaa Rashied (Author), Fifi Mostafa Elsayed (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020) -
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018) -
Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis
by: Xin Guan, et al.
Published: (2024) -
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
by: Rossana Roncato, et al.
Published: (2022) -
The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow's oncologists
by: L. G. Zhukova, et al.
Published: (2020)